NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
News|Articles|November 1, 2018
- Pharmaceutical Technology\'s In the Lab eNewsletter-11-07-2018
- Volume 13
- Issue 11
Velesco Pharma Acquires New R&D and cGMP Analytical Lab
Author(s)Pharmaceutical Technology Editors
he acquisition expands the company’s formulation and analytical R&D services.
Advertisement
Velesco Pharm, a development and clinical manufacturing company, has acquired a new facility in Wixom, MI, that expands and enhances its formulation and analytical R&D capabilities, the company announced on Oct. 23, 2018.
The acquisition and fit-out of the new facility double the company’s formulation and analytical laboratory space. The increase in capacity expands its research and cGMP services, including formulation development, analytical method development/validation, release and stability testing, and cGMP clinical manufacturing. The move to the expanded facility will occur before the end of 2018.
“Our new laboratory is impressively designed and equipped, and we will be increasing our scientific team such that we can meet our clients’ growing demand for pharmaceutical formulation and analytical services,” said Dave Barnes, PhD, CEO at Velesco, in a company press release.
Source:
Articles in this issue
almost 8 years ago
Improvement of Structural Profiling of N-glycans in Biologicsalmost 8 years ago
Advanced Flow Cytometry System Breaks the Cost Barrieralmost 8 years ago
Precision Powder Dispensing Technology Targets New Pharma Applicationsalmost 8 years ago
Vacuum Concentrators with Pre-Set and Custom-Made Programsalmost 8 years ago
Avid Bioservices Hits Milestone in Laboratory Expansionalmost 8 years ago
Agilent’s New Chemical Imaging System Enhances Visual Clarityalmost 8 years ago
Chip-Based Device May Transform Spectrometryalmost 8 years ago
SGS Adds In Vitro Toxicology Testing at Canadian LabAdvertisement
Related to this article
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Rare Disease Framework Puts CMC Review in Scope
2
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
3
PharmTech AI Pulse Check: AI Watermark Vulnerability
4
Using Automation to Enhance Manufacturing: Building the Foundation for Pharma 4.0
5